Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | MAP4K3 | Q8IVH8 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488336 | 0.90 | MET (0.48) | METMAP4K4MAP4K3JAK2FYN | |
| Water SCHEMBL28122580 | 0.90 | MET (0.56) | METMAP4K4MAP4K3JAK2FYN | |
| SCHEMBL487796 | 0.88 | MET (0.57) | METMAP4K4MAP4K3JAK2FYN | |
| SCHEMBL28756897 | 0.86 | MET (0.51) | METMAP4K4MAP4K3JAK2 | |
| SCHEMBL487592 | 0.86 | MET (0.73) | METMAP4K4FYN | |
| SCHEMBL30452529 | 0.86 | MET (0.73) | METMAP4K4FYN | |
| SCHEMBL6364739 | 0.85 | MET (0.75) | METMAP4K4MAP4K3JAK2PIK3CG | |
| SCHEMBL487688 | 0.81 | MAP4K4 (0.71) | METMAP4K4 | |
| SCHEMBL30454464 | 0.81 | MAP4K4 (0.71) | METMAP4K4 | |
| SCHEMBL488145 | 0.80 | MET (0.68) | METMAP4K4MAP4K3JAK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885MAP4K4 40/4885MAP4K3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.